Optimizing GWG in Obese Pregnant Women: A Nationwide Real-World Study Using the U.S. Natality Cohort
Public ClinicalTrials.gov record NCT07796815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Optimizing Gestational Weight Gain in Obese Pregnant Women: A Nationwide Real-World Study Using the U.S. Natality Cohort
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this observational study is to find out which amount of weight gain during pregnancy is safest for women with obesity and their babies. Current guidelines recommend the same weight gain target (5 to 9 kg) for all women with obesity. However, obesity has different levels of severity. The same target may not work well for everyone. Researchers will look at health data from about 10 million U.S. birth records between 2023 and 2025. They will focus on women aged 18 to 45 who had a single baby at full term (37 to 41 weeks) and had obesity before pregnancy. All women in this study started prenatal care in their first 3 months of pregnancy. The study divides total pregnancy weight gain into 8 different ranges. Then, it checks for maternal and newborn health problems. Serious problems include stays in the intensive care unit (ICU) or blood transfusions. Moderate problems include high blood pressure during pregnancy, diabetes, or babies born too large or too small. By comparing weight gain ranges across three obesity classes, this study aims to find specific target weight ranges for each class. The ultimate goal is to lower the risk of both severe and moderate pregnancy complications for mothers and their newborns
Study identification
- NCT ID
- NCT07796815
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Shanghai First Maternal and Infant Health Hospital affiliated to Tongji University Medical School
- Other
- Enrollment
- 1,600,000 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2022
- Primary completion
- Dec 30, 2025
- Completion
- Dec 30, 2025
- Last update posted
- Aug 31, 2026
2023 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Vital Statistics System (NVSS) - United States | Hyattsville | Maryland | 20782 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07796815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07796815 live on ClinicalTrials.gov.